HOME ·

01276.HK

HENGRUI PHARMA (01276.HK): HRS-4729 Injection Approved for Phase II Clinical Trial in Type 2 Diabetes
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-12
HENGRUI PHARMA (01276.HK): Trastuzumab Rezetecan Approved for Third Indication, Becoming China's First Anti-HER2 Product Approved for Colorectal Cancer
Tags：
HENGRUI PHARMA01276.HKIndications approved
2026-08-06
HENGRUI PHARMA (01276.HK): Class 1 Innovative Drug Ivarmacitinib Sulfate Tablets Approved for Fifth Indication, Completing Full-Disease-Spectrum Coverage of Axial Spondyloarthritis
Tags：
HENGRUI PHARMA01276.HKbiopharmaceutical
2026-08-06
HENGRUI PHARMA(01276.HK): SHR‑A2009 for Injection Combined with Adebrelimab Obtains NMPA Clinical Trial Approval for Non‑Small‑Cell Lung Cancer
Tags：
HENGRUI PHARMA01276.HKClinical Trial
2026-08-04
Metis TechBio-P (07666.HK): AiTEM AI Formulation Platform Partners with HENGRUI PHARMA to Accelerate Drug Formulation Development
Tags：
METIS TECHBIO-P07666.HKHENGRUI PHARMA01276.HKAiTEM
2026-08-03
Jiangsu Hengrui Pharmaceuticals (01276.HK): HRS5580 for Injection Obtains Clinical Trial Approval Notice
Tags：
Jiangsu Hengrui Pharmaceuticals01276.HK
2026-07-30
Jiangsu Hengrui Pharmaceuticals (01276.HK): Insulin Sudelidec Injection Approved for Marketing by NMPA
Tags：
Jiangsu Hengrui Pharmaceuticals01276.HK
2026-07-30
Hengrui Pharmaceuticals (01276.HK): SHR-4375 Injection Granted FDA Orphan Drug Designation
Tags：
Hengrui Pharmaceuticals01276.HK
2026-07-28
Hengrui Pharmaceuticals (01276.HK): HRS-1780 Tablets Obtains Clinical Trial Approval Notice
Tags：
Hengrui Pharmaceuticals01276.HK
2026-07-28
Hengrui Pharmaceuticals(01276.HK): Injection HRS9531 Obtains Clinical Trial Approval Notice
Tags：
Hengrui Pharmaceuticals01276.HK
2026-07-16
Hengrui Pharmaceuticals(01276.HK): Concentrated Solution for Injection HRS-8829 Receives Clinical Trial Approval Notice
Tags：
Hengrui Pharmaceuticals01276.HK
2026-07-15
Hengrui Pharmaceuticals(01276.HK): Injection SHR-3079 Obtains Clinical Trial Approval Notice
Tags：
Hengrui Pharmaceuticals01276.HK
2026-07-13
HENGRUI PHARMA (01276.HK): Receives CRL from FDA for Camrelizumab Liver Cancer Indication, Related to cGMP Inspection Findings at Apatinib Manufacturing Site
Tags：
HENGRUI PHARMA01276.HKPharmaceutical Updates
2026-07-10
HENGRUI PHARMA (01276.HK): SHR-4685 Injection Obtains Clinical Trial Approval for Advanced Solid Tumours
Tags：
HENGRUI PHARMA01276.HKClinical Trial Application
2026-07-07
Hengrui Medicine (01276.HK) Adebrelimab Becomes First Domestic PD-L1 Inhibitor for NSCLC Perioperative Setting
Tags：
Hengrui Medicine01276.HKA+H
2026-06-25
Hengrui Medicine (01276.HK): Marketing Authorization Application for Relugolix Tablets Accepted by EMA
Tags：
Hengrui Medicine01276.HK
2026-06-22
Hengrui Medicine (01276.HK): SHR-6914 Injection Approved for Clinical Trials
Tags：
Hengrui Medicine01276.HK
2026-06-16
Hengrui Pharma (01276.HK): Enters Global Strategic Collaboration with Bristol Myers Squibb, Total Transaction Value Up to ~US$15.2 Billion
Tags：
HENGRUI PHARMA01276.HKStrategic Collaboration
2026-05-12
HENGRUI PHARMA (01276.HK): Five Innovative Drugs Obtain Clinical Trial Approvals, Targeting KRAS G12D and Other Indications
Tags：
HENGRUI PHARMA01276.HKNotice of Approval for Clinical Trials
2026-05-09
HENGRUI PHARMA(01276.HK): HRS-3005 Tablets Granted Clinical Trial Approval for B-Cell Malignancies
Tags：
HENGRUI PHARMA01276.HKNotice of Approval for Clinical Trials
2026-05-09
Previous1 23